Medicare extends home hospital care before safety study is done

What it does

This bill extends Medicare's experimental 'Hospital Care at Home' program—which allows certain patients to receive acute inpatient-level care in their homes instead of hospitals—through September 30, 2030. It also requires the Department of Health and Human Services to conduct a detailed study by September 2028 comparing outcomes, costs, quality, and patient experience between home-based care and traditional hospital inpatient care, with $2.5 million appropriated for the study. The bill does not change eligibility or coverage rules; it extends an existing waiver and mandates evidence-gathering on whether the program works.

Why we flagged it

The bill's core function is to extend an existing Medicare waiver program and require a study on its effects. It is neither a deregulation nor a carve-out, but a conditional extension tied to evidence-gathering—a pragmatic but cautious approach to an experimental program.

What the text implies

• The waiver extension runs through 2030 while the mandated study is not due until September 2028, meaning the program will operate for two additional years after the study concludes with no requirement to act on findings—creating a lag between evidence and policy adjustment.
• The bill does not specify what happens if the study finds poor outcomes, cost overruns, or safety concerns; there is no automatic sunset or adjustment mechanism tied to study results.
• Home-based acute care may shift labor composition (increased contracted labor, reduced nursing ratios) and reduce hospital utilization, potentially affecting hospital employment and revenue—outcomes the study will measure but the bill does not restrict.
• The $2.5M appropriation for a multi-year, multi-hospital comparative study is relatively small; underfunding may limit the study's ability to detect safety or quality issues, particularly for rare adverse events or subpopulations.
• Socioeconomic and racial/ethnic data collection is mandated, but the bill does not require equity analysis or corrective action if disparities are found—data collection without accountability.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens may benefit from expanded access to home-based acute care (convenience, potentially lower infection risk, family involvement), but the program's long-term safety, quality, and cost-effectiveness remain unproven. The bill extends the waiver before the mandated study is complete, creating a risk that poor outcomes or cost overruns could harm beneficiaries or Medicare's solvency. The $2.5M study appropriation is modest relative to the program's scale, raising questions about evidence quali

Who stands to gain

• home health agencies and telehealth providers (expanded service volume under extended waiver)
• hospitals participating in the program (potential cost savings if home care is cheaper than inpatien
• medical equipment suppliers (home monitoring, telehealth infrastructure)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), House Committee on Ways and Means, Senate Committee on Finance, Medicare, Medicaid (Title XIX, for dual-eligible analysis), Acute Hospital Care at Home initiative, UnitedHealth Group (UNH), Universal Health Services (UHS), Medtronic (MTD), Encompass Health (GH), LHC Group (LHCG) — implied home health provider

Where it stands

8 cosponsors: 7 Republicans, 1 Democrats.

• Jul 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 10, 2025 — Referred to House Committee on Ways and Means and Senate Committee on Finance · Congress.gov: “Referred to the House Committee on Ways and Means”
• Sep 17, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Sep 17, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 44 - 0”
• Dec 1, 2025 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4935)”
• Dec 1, 2025 — Floor vote scheduled · Congress.gov: “Mr. Smith (MO) moved to suspend the rules and pass the bill, as amended”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

16 lobbying clients named this bill on 19 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $6,545,619 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

Vern Buchanan, the sponsor, reported $544,700 in PAC receipts in the 2026 cycle.

• AARP — $5,300,000 on 1 filing
• National Association of Accountable Care Organizations — $276,869 on 2 filings
• The Metrohealth System — $210,000 on 1 filing
• Alliance for Connected Care — $200,000 on 1 filing
• Moving Health Home — $110,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.